Easterly Investment Partners LLC Buys New Stake in Haemonetics Corporation (NYSE:HAE)

Easterly Investment Partners LLC acquired a new stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 30,831 shares of the medical instruments supplier's stock, valued at approximately $1,959,000. Easterly Investment Partners LLC owned 0.06% of Haemonetics as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Norges Bank bought a new stake in Haemonetics during the 4th quarter valued at $32,803,000. Voya Investment Management LLC raised its position in Haemonetics by 820.5% during the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after purchasing an additional 282,521 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Haemonetics by 434.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock valued at $24,522,000 after purchasing an additional 255,338 shares in the last quarter. Groupama Asset Managment bought a new stake in Haemonetics during the 4th quarter valued at $19,520,000. Finally, Raymond James Financial Inc. bought a new stake in Haemonetics during the 4th quarter valued at $19,002,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a research report on Wednesday, July 9th. Robert W. Baird started coverage on Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target for the company. Finally, Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $97.30.

Haemonetics Stock Down 1.2%

NYSE:HAE traded down $0.90 during mid-day trading on Friday, hitting $72.55. 738,041 shares of the company's stock traded hands, compared to its average volume of 681,083. The company has a fifty day moving average of $71.63 and a 200 day moving average of $67.86. Haemonetics Corporation has a twelve month low of $55.30 and a twelve month high of $94.99. The company has a market capitalization of $3.49 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.18 and a beta of 0.39. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company's revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.90 earnings per share. On average, analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.